Flutiform K-haler contains the corticosteroid fluticasone and the long-acting β2 agonist (LABA) formoterol in a breath-actuated metered-dose aerosol inhaler.
It is indicated in adults and adolescents from 12 years for the regular treatment of asthma where the use of a combination product (an inhaled corticosteroid and a long-acting β2 agonist) is appropriate.
According to the manufacturer, Napp Pharmaceuticals, the K-haler has a patented ‘kinked’ valve that is activated by low inspiratory force, making it easier to use correctly.
The inhaler can be used in patients not adequately controlled with inhaled corticosteroids and 'as required' inhaled short-acting β2 agonist, and in patients already adequately controlled on both an inhaled corticosteroid and a long-acting β2 agonist.
Flutiform K-haler is available in two strengths, 50/5 microgram and 125/5 microgram, and is taken as two puffs twice daily.
Flutiform already exists as a regular 'press and breathe' metered-dose inhaler, available in three strengths with the same dose schedule of two puffs twice daily.